Amedisys (AMED) Tops Q4 EPS by 1c, Revs Miss

Amedisys (NASDAQ: AMED) reported Q4 EPS of $0.94, $0.01 better than the analyst estimate of $0.93. Revenue for the quarter came in at $500.7 million versus the consensus estimate of $511.55 million.

Paul B. Kusserow, Chairman, President and Chief Executive Officer stated, “I am very proud of our fourth quarter and year end results as we continued our trend of outperformance this year. We have stayed true to our mission of providing clinically excellent care to our patients no matter where they call home, and it has once again translated into stellar financial results. None of this would be possible without the unwavering dedication of our over 21,000 employees, and I thank each and every one of you for your continued commitment to our patients. We are set up for a great 2020 as we navigate the waters of PDGM, and I look forward to another year of outperformance.”

GUIDANCE:

Amedisys sees FY2020 EPS of $4.90-$5.13, versus the consensus of $4.91. Amedisys sees FY2020 revenue of $2.115-2.16 billion, versus the consensus of $2.12 billion.

For earnings history and earnings-related data on Amedisys (AMED) click here.

You May Also Be Interested In

• Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
• Equinor ASA (EQNR) Tops Q1 EPS by 22c, misses on revenue
• Tractor Supply (TSCO) Tops Q1 EPS by 12c ; Offers Guidance